References
- Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift?. JAMA 2000; 283: 373–80
- Rutledge P, Crookes D, McKinstry B, Maxwell SR. Do doctors rely on pharmaceutical industry funding to attend conferences and do they perceive that this creates a bias in their drug selection? Results from a questionnaire survey. Pharmacoepidemiol Drug Saf 2003; 12: 663–7
- Blumenthal D. Doctors and drug companies. N Engl J Med 2004; 351: 1885–90
- Abbasi K, Smith R. No more free lunches. BMJ 2003; 326: 1155–6
- Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 1996; 5: 201–6
- Aasland OG, Forde R. [Physicians and drug industry: Attitudes and practice]. Tidsskr Nor Laegeforen 2004; 124: 2603–6
- Figueras A, Laporte JR. Failures of the therapeutic chain as a cause of drug ineffectiveness. BMJ 2003; 326: 895–6
- Caudill T, Lurie N, Rich E. The influence of pharmaceutical industry advertising on physician prescribing. J Drug Issues 1992; 22: 331–8
- Watkins C, Harvey I, Carthy P, Moore L, Robinson E, Brawn R. Attitudes and behaviour of general practitioners and their prescribing costs: A national cross sectional survey. Qual Saf Health Care 2003; 12: 29–34
- Groves KE, Sketris I, Tett SE. Prescription drug samples: Does this marketing strategy counteract policies for quality use of medicines?. J Clin Pharm Ther 2003; 28: 259–71
- Morelli D, Koenigsberg MR. Sample medication dispensing in a residency practice. J Fam Pract 1992; 34: 42–8
- Peay MY, Peay ER. Patterns of preference for information sources in the adoption of new drug by specialists. Soc Sci Med 1990; 31: 467–76
- Rotwitt L, Rosholm JU, Brøsen K, Gram LF. [Nature and extent of drug information to general practitioners: A questionnaire study]. Ugeskr Laeger 1989; 151: 647–50
- Andersen M, Kragstrup J, Søndergaard J. How conducting a clinical trial affects physicians’ guideline adherence and drug preferences. JAMA 2006; 23: 2759–64
- Husby T. [Cooperation between physicians and pharmaceutical consultants: A questionnaire study]. Tidsskr Nor Laegeforen 1991; 111: 2758–60
- Prosser H, Walley T. New drug uptake: Qualitative comparison of high and low prescribing GPs’ attitudes and approach. Fam Pract 2003; 20: 583–91
- Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med 1988; 26: 1183–9
- Simon SR, Majumdar SR, Prosser LA, Salem-Schatz S, Warner C, Kleinman K, et al. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: A cluster-randomized controlled trial. Am J Med 2005; 118: 521–8
- Prosser H, Almond S, Walley T. Influences on GPs’ decision to prescribe new drugs: The importance of who says what. Fam Pract 2003; 20: 61–8
- Petursson P. GPs’ reasons for “non-pharmacological” prescribing of antibiotics: A phenomenological study. Scand J Prim Health Care 2005; 23: 120–5
- Søndergaard J, Foged A, Kragstrup J, Gaist D, Gram LF, Sindrup SH, et al. Intensive community pharmacy intervention had little impact on triptan consumption: A randomized controlled trial. Scand J Prim Health Care 2006; 24: 16–21